DK1649023T3 - Polypeptid med forbedret cytosindeaminaseaktivitet - Google Patents

Polypeptid med forbedret cytosindeaminaseaktivitet

Info

Publication number
DK1649023T3
DK1649023T3 DK04744156T DK04744156T DK1649023T3 DK 1649023 T3 DK1649023 T3 DK 1649023T3 DK 04744156 T DK04744156 T DK 04744156T DK 04744156 T DK04744156 T DK 04744156T DK 1649023 T3 DK1649023 T3 DK 1649023T3
Authority
DK
Denmark
Prior art keywords
polypeptide
enhanced
cytosine deaminase
deaminase activity
activity
Prior art date
Application number
DK04744156T
Other languages
Danish (da)
English (en)
Inventor
Philippe Erbs
Original Assignee
Transgene Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Transgene Sa filed Critical Transgene Sa
Application granted granted Critical
Publication of DK1649023T3 publication Critical patent/DK1649023T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/78—Hydrolases (3) acting on carbon to nitrogen bonds other than peptide bonds (3.5)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Virology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Physics & Mathematics (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
DK04744156T 2003-07-21 2004-06-29 Polypeptid med forbedret cytosindeaminaseaktivitet DK1649023T3 (da)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP03360087 2003-07-21
US50827403P 2003-10-06 2003-10-06
PCT/IB2004/002505 WO2005007857A1 (en) 2003-07-21 2004-06-29 Polypeptide having an improved cytosine deaminase activity

Publications (1)

Publication Number Publication Date
DK1649023T3 true DK1649023T3 (da) 2008-10-06

Family

ID=39719832

Family Applications (1)

Application Number Title Priority Date Filing Date
DK04744156T DK1649023T3 (da) 2003-07-21 2004-06-29 Polypeptid med forbedret cytosindeaminaseaktivitet

Country Status (17)

Country Link
US (3) US7790445B2 (ko)
EP (2) EP1649023B1 (ko)
JP (1) JP4672659B2 (ko)
KR (1) KR101062140B1 (ko)
CN (1) CN1826410B (ko)
AT (1) ATE405654T1 (ko)
AU (1) AU2004257935B2 (ko)
CA (1) CA2532783C (ko)
CY (1) CY1110397T1 (ko)
DE (1) DE602004015995D1 (ko)
DK (1) DK1649023T3 (ko)
ES (1) ES2311831T3 (ko)
HK (2) HK1084150A1 (ko)
IL (1) IL173158A (ko)
PL (1) PL1649023T3 (ko)
PT (1) PT1649023E (ko)
WO (1) WO2005007857A1 (ko)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2551982C2 (ru) 2006-06-20 2015-06-10 Трансжене С.А. Способ получения поксвирусов и композиции поксвирусов
BRPI0811787B1 (pt) 2007-07-03 2018-10-09 Transgene Sa usos de uma célula imortalizada e processo para imortalizar uma célula aviária
US8357531B2 (en) 2007-07-03 2013-01-22 Transgene S.A. Immortalized avian cell lines
WO2010045002A2 (en) * 2008-09-26 2010-04-22 Tocagen Inc. Gene therapy vectors and cytosine deaminases
BRPI1007744A2 (pt) 2009-05-12 2017-06-27 Transgene Sa método para a produção e purificação de um ortopoxvírus do tipo selvagem, ortopoxvírus do tipo selvagem, composição farmacêutica, uso de um ortopoxvírus do tipo selvagem e uso de uma linhagem de células aviárias imortalizadas
AU2010275764A1 (en) 2009-07-21 2012-03-15 Transgene Sa Enzymatic composition for the digestion of chicken embryos
EP2527432A1 (en) * 2011-05-23 2012-11-28 Novozymes A/S Bi-directional cytosine deaminase-encoding selection marker
WO2013004658A1 (en) 2011-07-01 2013-01-10 Transgene Sa Formulations of 5-fluorocytosine and uses thereof.
US9642921B2 (en) 2012-12-20 2017-05-09 Tocagen Inc. Cancer combination therapy and recombinant vectors
EP3129037B1 (en) 2014-04-10 2019-11-13 Transgene Poxviral oncolytic vectors
US10555981B2 (en) 2014-07-16 2020-02-11 Transgene S.A. Oncolytic virus for expression of immune checkpoint modulators
CN107206063B (zh) 2014-12-01 2021-09-28 特兰斯吉恩股份有限公司 稳定的液体痘苗病毒制剂
CA2975432A1 (en) * 2015-02-13 2016-08-18 Transgene Sa Immunotherapeutic vaccine and antibody combination therapy
US20190134190A1 (en) 2016-05-04 2019-05-09 Transgene Sa Combination therapy with cpg tlr9 ligand
US20190336552A1 (en) 2016-05-30 2019-11-07 Astellas Pharma Inc. Genetically engineered vaccinia viruses
US10888594B2 (en) * 2016-05-30 2021-01-12 National University Corporation Tottori University Genetically engineered vaccinia viruses
WO2018091680A1 (en) 2016-11-18 2018-05-24 Transgene Sa Cowpox-based oncolytic vectors
WO2019020543A1 (en) 2017-07-28 2019-01-31 Transgene Sa ONCOLYTIC VIRUSES EXPRESSING AGENTS TARGETING METABOLIC IMMUNE MODULATORS
JP2021516957A (ja) 2018-03-07 2021-07-15 トランジェーヌＴｒａｎｓｇｅｎｅ パラポックスウイルスベクター
WO2020011754A1 (en) 2018-07-09 2020-01-16 Transgene Chimeric vaccinia viruses
CA3113965A1 (en) 2018-09-26 2020-04-02 Astellas Pharma Inc. Cancer therapy by combination use of oncolytic vaccinia virus and immune checkpoint inhibitor, and pharmaceutical composition and combination medicine for use in the cancer therapy
WO2023213763A1 (en) 2022-05-02 2023-11-09 Transgene Poxvirus encoding a binding agent comprising an anti- pd-l1 sdab
WO2023213764A1 (en) 2022-05-02 2023-11-09 Transgene Fusion polypeptide comprising an anti-pd-l1 sdab and a member of the tnfsf
WO2024038175A1 (en) 2022-08-18 2024-02-22 Transgene Chimeric poxviruses

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4603112A (en) 1981-12-24 1986-07-29 Health Research, Incorporated Modified vaccinia virus
FR2583429B1 (fr) 1985-06-18 1989-11-03 Transgene Sa Vecteur d'expression de l'interferon u dans les cellules de mammifere, procede pour sa mise en oeuvre et produit obtenu et composition pharmaceutique contenant l'interferon u
CA2018273C (en) * 1989-06-09 1999-04-06 Peter D. Senter Thermally stable cytosine deaminase
US5358866A (en) 1991-07-03 1994-10-25 The United States Of America As Represented By The Department Of Health And Human Services Cytosine deaminase negative selection system for gene transfer techniques and therapies
AU682854B2 (en) 1993-02-16 1997-10-23 Onyx Pharmaceuticals Cytopathic viruses for therapy and prophylaxis of neoplasia
AU6953394A (en) * 1993-05-21 1994-12-20 Targeted Genetics Corporation Bifunctional selectable fusion genes based on the cytosine deaminase (cd) gene
FR2705686B1 (fr) 1993-05-28 1995-08-18 Transgene Sa Nouveaux adénovirus défectifs et lignées de complémentation correspondantes.
FR2722208B1 (fr) 1994-07-05 1996-10-04 Inst Nat Sante Rech Med Nouveau site interne d'entree des ribosomes, vecteur le contenant et utilisation therapeutique
US5856153A (en) 1994-11-17 1999-01-05 Cayla Suicide genes and new associations of pyrimidine nucleobase and nucleoside analogs with new suicide genes for gene therapy of acquired diseases
FR2727689A1 (fr) 1994-12-01 1996-06-07 Transgene Sa Nouveau procede de preparation d'un vecteur viral
FR2737222B1 (fr) 1995-07-24 1997-10-17 Transgene Sa Nouveaux vecteurs viraux et lignee pour la therapie genique
FR2759382A1 (fr) 1997-02-10 1998-08-14 Transgene Sa Nouveaux composes et compositions les contenant utilisables pour le transfert d'au moins une substance therapeutiquement active, notamment un polynucleotide, dans une cellule cible et utilisation en therapie genique
FR2762615B1 (fr) 1997-04-28 1999-07-16 Inst Nat Sante Rech Med Nouveau site interne d'entree des ribosomes et vecteur le contenant
FR2777570A1 (fr) * 1998-04-17 1999-10-22 Transgene Sa Mutant ayant une activite phosphoribosyl transferase
US6552005B1 (en) 1998-09-29 2003-04-22 Uab Research Foundation Molecular chemotherapy enhancement of radiotherapy
US20030121068A1 (en) * 2001-11-30 2003-06-26 Paul Orchard Vector encoding suicide and marker constructs
US7141404B2 (en) * 2002-12-27 2006-11-28 Onyx Pharmaceuticals, Inc. Candida kefyr cytosine deaminase

Also Published As

Publication number Publication date
EP1897938A1 (en) 2008-03-12
JP2006527994A (ja) 2006-12-14
CA2532783C (en) 2013-09-17
US7790445B2 (en) 2010-09-07
HK1112024A1 (en) 2008-08-22
US8257692B2 (en) 2012-09-04
CY1110397T1 (el) 2015-04-29
IL173158A0 (en) 2006-06-11
AU2004257935B2 (en) 2009-11-19
PT1649023E (pt) 2008-11-20
AU2004257935A1 (en) 2005-01-27
PL1649023T3 (pl) 2009-01-30
EP1649023B1 (en) 2008-08-20
IL173158A (en) 2009-12-24
EP1649023A1 (en) 2006-04-26
EP1897938B1 (en) 2010-10-06
HK1084150A1 (en) 2006-07-21
US20100330051A1 (en) 2010-12-30
CN1826410B (zh) 2011-10-26
KR20060040697A (ko) 2006-05-10
DE602004015995D1 (de) 2008-10-02
KR101062140B1 (ko) 2011-09-05
ATE405654T1 (de) 2008-09-15
CA2532783A1 (en) 2005-01-27
CN1826410A (zh) 2006-08-30
WO2005007857A1 (en) 2005-01-27
JP4672659B2 (ja) 2011-04-20
EP1897938B9 (en) 2011-08-31
US20100330031A1 (en) 2010-12-30
US20070264235A1 (en) 2007-11-15
ES2311831T3 (es) 2009-02-16
US8226954B2 (en) 2012-07-24

Similar Documents

Publication Publication Date Title
HK1084150A1 (en) Polypeptide having an improved cytosine deaminase activity
ATE417595T1 (de) Keratin-bindende polypeptide
BRPI0517493A (pt) polinucleotìdeo isolado, promotor vetor de expressão, célula hospedeira e uso de um polinucleotìdeo
CY1110028T1 (el) Πολυπεπτιδια για την επαγωγη προστατευτικης ανοσοαπαντησης εναντι του staphylococcus aureus
EA201200398A1 (ru) Полипептиды с оксидоредуктазной активностью и их применение
DK1454138T3 (da) Immunocytokiner med moduleret selektivitet
ATE435923T1 (de) Neue polynukleotide und polypeptide des erythropoietingens
DK1423419T3 (da) Hybrid- og tandemekspression af Neisseria-proteiner
ATE462000T1 (de) Verfahren zur herstellung von l-arginin, l- ornithin oder l-citrullin
ATE497975T1 (de) Il-21-varianten
RS51325B (sr) Polipeptidi koji imaju antimikrobno dejstvo i polinukleotidi koji ih kodiraju
DE60335549D1 (de) Gewinnung von Hitzeschockproteinen
DK1778271T3 (da) Peptid til behandling af herpesvirusinfektioner
SG146640A1 (en) Isolated photoprotein mtclytin, and use thereof
ATE414156T1 (de) Lipase-varianten
DE602005025989D1 (de) Von 2',3'-didesoxynucleosiden und 2',3'-didehydro-2',3'-didesoxynucleosiden
NO20051938L (no) Promoter til IL-18BP, dens fremstilling og anvendelse
NO20082864L (no) Nytt polypeptid med esteraseaktivitet og rekombinant esterase samt anvendelse derav
FR2902101B1 (fr) Peptides a activite anti-proliferative
WO2003072733A3 (en) Modified bace
TW200617021A (en) Isolated photoprotein aequorin y89f, and its use
ATE387494T1 (de) Hitzelabile desoxyribonuklease i-varianten
GB2441941A (en) An isolated recombinant vaccinia virus complement control protein (HRVCP) polypeptide
TW200716666A (en) Isolated photoprotein gr-bolinopsin, and its use